Last reviewed 2026-04-19 · How we verify

RDEA119

Bayer · Phase 1 active Small molecule

At a glance

Generic name	RDEA119
Also known as	Refametinib;, RDEA119;, BAY 86-9766
Sponsor	Bayer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients (PHASE1)
Japanese BAY86-9766 Monotherapy Phase I Study (PHASE1)
RDEA119 and Sorafenib Combination Dose Escalation Study (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RDEA119 CI brief — competitive landscape report
RDEA119 updates RSS · CI watch RSS
Bayer portfolio CI